Shopping Cart
Remove All
Your shopping cart is currently empty
Emibetuzumab (Synonyms: LY2875358)
Catalog No. T76743 Copy Product Info
Purity: 95%
😃Good
Emibetuzumab is a potent humanized bivalent MET antibody (IgG4 type). Emibetuzumab has antitumor activity, inhibition of HGF-dependent and independent MET pathway activation and tumor growth, and can be used to study advanced castration-resistant prostate cancer.
Emibetuzumab
Copy Product Info😃Good
Catalog No. T76743
Synonyms LY2875358
Emibetuzumab is a potent humanized bivalent MET antibody (IgG4 type). Emibetuzumab has antitumor activity, inhibition of HGF-dependent and independent MET pathway activation and tumor growth, and can be used to study advanced castration-resistant prostate cancer.
Emibetuzumab
Cas No. 1365287-97-3
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 1 mg | $147 | In Stock | In Stock | |
| 5 mg | $447 | In Stock | In Stock | |
| 10 mg | $713 | In Stock | In Stock |
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
With extensive experience in compound synthesis, we can provide rapid custom synthesis services for this product according to your research needs.
For research use only—not for human use. No sales to individuals. Use as intended only.
Batch Information
Select Batch
Purity:96.5% (SDS-PAGE); 98.8% (SEC-HPLC)
Appearance:Liquid
Color:Transparent
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | Emibetuzumab is a potent humanized bivalent MET antibody (IgG4 type). Emibetuzumab has antitumor activity, inhibition of HGF-dependent and independent MET pathway activation and tumor growth, and can be used to study advanced castration-resistant prostate cancer. |
| In vitro | Emibetuzumab (LY2875358) inhibits HGF-stimulated proliferation of H596 at a concentration of 100 nmol/L for 6 days[1]. |
| In vivo | Emibetuzumab (LY2875358) exhibits antitumor effects on MET-amplified xenograft mouse tumor models. It inhibits in vivo growth of glioblastoma U87MG xenograft tumors in mice at a dose of 10 mg/kg via intravenous administration once a week for 5 weeks. Additionally, a single intravenous dose of 10 or 20 mg/kg results in the downregulation of MET and pMET levels in the tumors of mice. The antitumor effects persist when administered once a week for 3, 5, or 6 weeks at a dose of 10 mg/kg[1]. |
| Synonyms | LY2875358 |
| Reactivity | Human |
| Verified Activity | Immobilized Human HGFR/c-Met Protein (His) (TMPY-01296) at 1 μg/mL (100 μL/well) can bind Emibetuzumab. The EC50 is 2.26 ng/mL.  |
| Application | Functional assay |
| Antibody Type | Monoclonal |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Gene ID | |
| Uniprot ID | |
| Target | HGFR/c-Met |
| Molecular Weight | 143.74 kDa |
| Cas No. | 1365287-97-3 |
| Isotype | Human IgG4 kappa |
| Recommended Isotype Control |
| Storage | -20°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
Calculator
Preview
Related Tags: buy Emibetuzumab | purchase Emibetuzumab | Emibetuzumab cost | order Emibetuzumab | Emibetuzumab in vivo | Emibetuzumab in vitro | Emibetuzumab molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.